Stockreport

KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD

KemPharm, Inc.  (KMPH) 
Last kempharm, inc. earnings: 2/28 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.kempharm.com/investor-overview
PDF Results Suggest that Data from Single Classroom-style Efficacy Study May Be Applicable Across Pediatric, Adolescent and Adult ADHD Patient Populations CORALVILLE, Iow [Read more]